AGMT
  • Die AGMT
    • Über uns
    • Vorstand
    • Team
    • Partner
    • Karriere
    • Kontakt
  • Studien
    • Hodgkin Lymphom
      • HD 21
      • AERN
      • BRESELIBET
    • Non-Hodgkin Lymphom
      • DSHNHL_NIVEAU
      • ORACLE
      • Pola-R-ICE
    • Multiples Myelom
      • MM-4
    • Pankreaskarzinom
      • DIsCOvER
    • COVID-19
      • INSERM_DisCoVeRy
  • Register
    • AIHA Registry
    • aMYELOIDr
    • ARIADNE NIS
    • CLL-Register
    • COVID-19 Register
    • LungCA Register
    • MBC Register
    • NGS Register
    • PTCL Register
  • Veranstaltungen
    • AGMT Jahresmeeting
    • Breast Cancer Talk
    • GI Cancer Summit
  • Publikationen
  • News
    • News Übersicht
    • Newsletter
    • News Archiv
  • Kontakt
  • AAA
  • Login
  • de
    Languages
    • en English
    • de Deutsch

AGMT_MBC Registry

Metastatic breast cancer in Austria

Synopsis

Short title: AGMT_MBC-Registry

Title: Metastatic breast cancer in Austria

Status: open

Start: June 2015

Coordinating Investigator: Univ. Prof. Dr. Richard Greil

NIS Number: NIS004886

Number of patients: 1607

Sponsor: AGMT gemeinnützige GmbH

Link to online CRF

Design

This registry is a prospective and retrospective, multicentre collection of data on patients with metastatic breast cancer in Austria. All tumour characteristics, medical histories and also treatment sequences are documented in anonymised form. For documentation in the registry, no further diagnostic or therapeutic measures are required than those already necessary in general. Participation in the registry must not interfere with treatment routines. A written consent must be obtained prior to the input of data. No informed consent is required from deceased patients.

Primary endpoints:

Epidemiological evaluations:

  • General characteristics of metastatic stage patients in Austria
  • Assessment of metastatic stage breast cancer subtypes in Austria
  • Assessment of the specific characteristics and frequency of metastatic breast cancer
  • Data on survival of female patients with metastatic breast cancer in Austria
  • Assessment of metastatic breast cancer therapies in Austria
  • Assessment of therapy response outside clinical studies
    • First-line therapy
    • Second-line therapy
    • Third and higher lines of therapy
Specific questions:

Specific questions are also investigated, such as the frequency of histology preparations from metastases, the frequency of histological discrepancies between primary tumour and metastasis, the importance of surgery of primary tumour and metastasis in metastatic breast cancer.

Inclusion criteria

Inclusion criteria (selected):
  • Histological evidence of breast cancer
  • Histological and/or radiological evidence of metastases
  • Metastasis within 10 years of registry initiation
  • Signed informed consent (if a patient has already died at the time of entry, the entry can be made without a declaration of consent)

Due to the non-interventional design of the registry there are no specific inclusion or exclusion criteria.

Register
  • Register
    • AIHA Register
    • aMYELOIDr
    • ARIADNE NIS
    • CLL-Register
    • COVID-19 Register
    • LungCA Register
    • MBC Register
    • NGS Register
    • PTCL Register
Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
Firmensitz und Rechnungsadresse: Gentzgasse 60/21, 1180 Wien
Zweigstelle & Zustelladresse: Wolfsgartenweg 31, 5020 Salzburg
Firmenbuchnummer: FN 289548 g
UID-Nummer: ATU63467108
+43 662 640 44 12
+ 43 664 142 25 04
+43 662 640 44 14
office@agmt.at
Copyright © AGMT gemeinnützige GmbH
  • Impressum
  • Datenschutzerklärung
  • LinkedIn AGMT